Table 1.
Clinical, pathological, genetic, and radiological features of metastatic hepatic uveal melanoma cohort at liver resection operation.
| Baseline Characteristics | Genetic Classification | |||
|---|---|---|---|---|
| Covariate | Label | All Cohort | High-Risk (n = 36) | Low/Intermediate-Risk (n = 27) |
| Age (years) | ≤60 | 29 (46%) | 14 (39%) | 15 (56%) |
| >60 | 34 (54%) | 22 (61%) | 12 (44%) | |
| Sex | Female | 30 (48%) | 17 (47%) | 13 (48%) |
| Male | 33 (52%) | 19 (53%) | 14 (52%) | |
| Largest basal diameter (mm) of primary tumor | ≤15 | 43 (68%) | 21 (58%) | 22 (81%) |
| >15 | 20 (32%) | 15 (42%) | 5 (19%) | |
| Ciliary involvement of primary tumor | No | 53 (84%) | 27 (75%) | 26 (96%) |
| Yes | 10 (16%) | 9 (25%) | 1 (4%) | |
| Retinal detachment of primary tumor | No | 41 (65%) | 23 (64%) | 18 (67%) |
| Yes | 22 (35%) | 13 (36%) | 9 (33%) | |
| Fundoscopic melanin evaluation of the primary tumor | NA | 4 (7%) | 0 (0%) | 4 (15%) |
| Absent | 2 (3%) | 1 (3%) | 1 (4%) | |
| Moderate | 14 (22%) | 7 (19%) | 7 (26%) | |
| Heavy | 43 (68%) | 28 (78%) | 15 (55%) | |
| Ocular tumor treatment | Enucleation | 29 (46%) | 20 (57%) | 9 (32%) |
| Proton beam/125I-plaque | 34 (54%) | 15 (43%) | 19 (68%) | |
| Disease-free interval between primary tumor and liver metastases (months) | ≤24 | 28 (44%) | 19 (53%) | 9 (33%) |
| >24 | 35 (56%) | 17 (47%) | 18 (67%) | |
| Size of liver metastases (mm) | ≤20 | 45 (71%) | 28 (78%) | 17 (63%) |
| >20 | 18 (29%) | 8 (22%) | 10 (37%) | |
| Number of liver metastases | ≤4 | 49 (78%) | 29 (81%) | 20 (74%) |
| >4 | 14 (22%) | 7 (19%) | 7 (26%) | |
| Miliary disease * | No | 27 (43%) | 11 (31%) | 16 (59%) |
| Yes | 36 (57%) | 25 (69%) | 11 (41%) | |
| T1 signal | ≤1.1 | 43 (68%) | 28 (78%) | 15 (56%) |
| >1.1 | 20 (32%) | 8 (22%) | 12 (44%) | |
| Histology type of liver metastases | Spindle | 19 (30%) | 9 (25%) | 10 (37%) |
| Epithelioid-mixed | 44 (70%) | 27 (75%) | 17 (63%) | |
| Loss of BAP1 of liver metastases | NA | 6 (10%) | 3 (8%) | 3 (11%) |
| No | 23 (37%) | 5 (14%) | 18 (67%) | |
| Yes | 34 (54%) | 28 (78%) | 6 (22%) | |
| Quality of liver resection | R0 | 51 (81%) | 26 (72%) | 25 (93%) |
| R2 | 12 (19%) | 10 (28%) | 2 (7%) | |
| Number of therapeutic lines after liver resection | ≤2 | 37 (59%) | 20 (56%) | 17 (63%) |
| >2 | 26 (41%) | 16 (44%) | 10 (37%) | |
| Systemic treatment | No | 12 (19%) | 3 (8%) | 9 (33%) |
| Yes | 51 (81%) | 33 (92%) | 18 (67%) | |
| Chemotherapy | No | 18 (29%) | 8 (22%) | 10 (37%) |
| Yes | 45 (71%) | 28 (78%) | 17 (63%) | |
| Immunotherapy | No | 27 (43%) | 12 (33%) | 15 (56%) |
| Yes | 36 (57%) | 24 (67%) | 12 (44%) | |
Data are expressed as n (%). High-genetic-risk refers to M3/8g abnormalities, and low/intermediate-risk refers to D3/8nl, D3/8g, or M3/8nl. * Miliary disease was defined radiologically by presence of at least three liver metastases of less than 5 mm. NA: not available.